Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 29;14:161. doi: 10.1007/s12672-023-00765-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — High expression of CAV1 renders the glioma cells OXPHOS inhibition. A Relative RNA expression of CAV1 in 9 cancer cells that we did RNA-sequencing, among which GB-1 and SF-126 are the human glioma cells. B The IC50 of all 57 cancer cell lines after treatment of Gboxin (the OXPHOS inhibitor) for 72 h. Glioma cancer cells SF-126 and GB-1 were marked. C The correlation between the expression of CAV1 and the OXPHOS-resistant cancer cell’s IC50. D Cell Viability test for SF-126 human glioma cancer cell line under Gboxin treatment in different dosages in 72 h. E The relative expression of CAV1 of OXPHOS-inhibition resistant cancer cell line, data from CCLE. F The relative expression of CAV1 of OXPHOS-inhibition sensitive cancer cell line, data from CCLE. G DepMap PRISM data shows more glioma cells under treatment with OXPHOS inhibitor Oligomycin A. The CERES scores were marked. H The GO/KEGG analysis of high-expressed genes in OXPHOS-inhibition groups. I The correlation between the expression of CAV1 in LGG gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. J The correlation between the expression of CAV1 in GBMLGG gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. K The correlation between the expression of CAV1 in GBM gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. L The correlation between the expression of CAV1 and HK2 in gliomas. M The correlation between expression of CAV1 and GLUT3 (SLC2A3) in gliomas. *p value < 0.05; **p value < 0.01;***p value < 0.001

Fig. 7 — High expression of CAV1 renders the glioma cells OXPHOS inhibition. A Relative RNA expression of CAV1 in 9 cancer cells that we did RNA-sequencing, among which GB-1 and SF-126 are the human glioma cells. B The IC50 of all 57 cancer cell lines after treatment of Gboxin (the OXPHOS inhibitor) for 72 h. Glioma cancer cells SF-126 and GB-1 were marked. C The correlation between the expression of CAV1 and the OXPHOS-resistant cancer cell’s IC50. D Cell Viability test for SF-126 human glioma cancer cell line under Gboxin treatment in different dosages in 72 h. E The relative expression of CAV1 of OXPHOS-inhibition resistant cancer cell line, data from CCLE. F The relative expression of CAV1 of OXPHOS-inhibition sensitive cancer cell line, data from CCLE. G DepMap PRISM data shows more glioma cells under treatment with OXPHOS inhibitor Oligomycin A. The CERES scores were marked. H The GO/KEGG analysis of high-expressed genes in OXPHOS-inhibition groups. I The correlation between the expression of CAV1 in LGG gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. J The correlation between the expression of CAV1 in GBMLGG gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. K The correlation between the expression of CAV1 in GBM gliomas with key OXPHOS genes including mt-CO1, mt-CO2 and mt-CO3. L The correlation between the expression of CAV1 and HK2 in gliomas. M The correlation between expression of CAV1 and GLUT3 (SLC2A3) in gliomas. *p value < 0.05; **p value < 0.01;***p value < 0.001